Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0DSOMP
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
LY3343544
|
|||||
| Synonyms |
LY-3343544; LY 3343544
Click to Show/Hide
|
|||||
| Organization |
Eli Lilly & Co.
|
|||||
| Drug Status |
Clinical candidate
|
|||||
| Indication |
In total 6 Indication(s)
Cholangiocarcinoma [ICD11:2C12]
Clinical candidate
Colorectal cancer [ICD11:2B91]
Clinical candidate
Gastric cancer [ICD11:2B72]
Clinical candidate
Head and neck cancer [ICD11:2B60-2B6E]
Clinical candidate
Non-small cell lung cancer [ICD11:2C25]
Clinical candidate
Pancreatic cancer [ICD11:2C10]
Clinical candidate
|
|||||
| Antibody Name |
Emibetuzumab
|
Antibody Info | ||||
| Antigen Name |
Hepatocyte growth factor receptor (MET)
|
Antigen Info | ||||
| Payload Name |
Monomethyl auristatin E
|
Payload Info | ||||
| Therapeutic Target |
Microtubule (MT)
|
Target Info | ||||
| Linker Name |
Undisclosed
|
|||||
| Conjugate Type |
Random conjugation through nucleophilic lysines.
|
|||||
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.